ArticleOpen veterinary journal2024
Promising antiviral inhibitors against lumpy skin disease: A vetinformatics approach.
Article in Open veterinary journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Research Review on Inhibitors of Lumpy Skin Disease Virus: From Biological Characteristics, Drug Repurposing, to Computer-Aided Drug Design.International journal of microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lumpy skin disease (LSD) is a transboundary virus disease that mostly affects cattle. It has recently been reported all over the world, which highlights the need for efficient control methods. LSD poses serious economic dangers worldwide. Aim: The aim of this study was to screen novel antiviral compounds for the control of LSD. Methods: By using Results: ADMET study of the selected 13 compounds revealed that Apigenin-4'-glucoside and Vidarabine did not show any critical hazards. The docking study identified potential antiviral compounds against LSDV, with Apigenin-4'-glucoside (ΔG = -6.6 ± 1.1) and Vidarabine (ΔG = -5.53 ± 0.73) showing promising interactions with key viral proteins. Molecular dynamics simulations confirmed the stability and robustness of these interactions, suggesting their potential as effective antiviral agents. Conclusion: Molecular analyses verify the strong antiviral activity of apigenin-4'-glucoside against LSDV among the selected compounds. This work sheds light on the way to explore potent anti-LSDV molecule. Moreover, the outcome of the study should screen after more extensive clinical studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.